Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.05 USD
Change Today +0.075 / 2.53%
Volume 125.3K
SQNM On Other Exchanges
As of 9:55 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/5/15 - $4.80
52 Week Low
11/20/14 - $2.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEQUENOM INC (SQNM)

sequenom inc (SQNM) Related Businessweek News

View More BusinessWeek News

sequenom inc (SQNM) Details

Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample. It also offers a microarray test that uses fetal samples obtained by amniocentesis or chorionic villus sampling under the NextView brand; additional carrier screening tests for Ashkenazi Jewish disorders, spinal muscular atrophy, and fragile X syndrome under the HerediT brand; and RetnaGene age-related macular degeneration (AMD) test to predict the risk of a patient with dry or early stage AMD progressing to wet or advanced choroidal neovascular disease within 2, 5, and 10 years. The company serves physicians and client laboratories. The company was founded in 1994 and is headquartered in San Diego, California.

448 Employees
Last Reported Date: 03/10/15
Founded in 1994

sequenom inc (SQNM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $433.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $343.9K
Chief Scientific & Strategy Officer, Executiv...
Total Annual Compensation: $407.6K
Senior Vice President of Corporate Governance...
Total Annual Compensation: $300.2K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $111.0K
Compensation as of Fiscal Year 2014.

sequenom inc (SQNM) Key Developments

Sequenom, Inc. Elects Catherine J. Mackey as New Member of its Board of Directors

Sequenom Inc. announced that its shareholders elected Catherine J. Mackey, Ph.D., as a new member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been appointed to the Audit and Nominating and Corporate Governance committees of the company's Board of Directors. Dr. Mackey is currently the Chief Executive Officer of CYPrus Therapeutics Inc.

Sequenom Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:30 PM

Sequenom Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 02:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: William J. Welch, Chief Executive Officer, President and Director.

Sequenom Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Sequenom Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $37.8 million, an increase of 2% compared to $37.1 million for the first quarter of 2014. Net earnings improved to $14.3 million, or $0.11 per diluted share as compared to a net loss of $15.7 million, or $0.13 per share, basic and diluted, for the first quarter of 2014. The improvement in the net earnings from the prior year is due to a $21.0 million gain on the pooled patents agreement with Illumina Inc., as well as improved gross margins and reduced operating expenses compared to the prior year first quarter. Operating income was $16.5 million as compared to operating loss of $14.4 million for the same period in 2014. Net cash used in operating activities was $7.2 million an improvement compared to $16.1 million for the first quarter of 2014. Earnings from continuing operations before income taxes were $14,360,000 against loss from continuing operations before income taxes of $16,545,000 a year ago. Purchases of property, equipment and leasehold improvements were $289,000 against $405,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $3.05 USD +0.075

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biotage AB kr17.10 SEK +0.10
Enzo Biochem Inc $2.96 USD +0.02
Luminex Corp $17.40 USD +0.18
NanoString Technologies Inc $15.29 USD +0.24
Pacific Biosciences of California Inc $5.63 USD -0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation SQNM Industry Range
Price/Earnings 23.7x
Price/Sales 2.4x
Price/Book NM Not Meaningful
Price/Cash Flow 11.8x
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at